

June 31, 2018

**For Immediate Release**

|                |  |
|----------------|--|
| Company name   | Otsuka Holdings Co., Ltd.                                    |
| Representative | Tatsuo Higuchi<br>President and Representative Director, CEO |
| Code number    | 4578 First Section , Tokyo Stock Exchange                    |
| Inquiries      | Yuji Kogure<br>Director, Investors Relations Department      |

**Otsuka and Lundbeck's Rxulti® (brexpiprazole) approved by the European Commission**

Otsuka Pharmaceutical Co., Ltd. (Otsuka) and H. Lundbeck A/S (Lundbeck) today announce that the European Commission has approved Rxulti® (brexpiprazole) for the treatment of schizophrenia in adults. The approval follows the positive opinion issued by the Committee for Medicinal Products for Human Use (CHMP) on May 31, 2018.

Lundbeck and Otsuka will now work with local pricing and reimbursement bodies in countries throughout Europe to help ensure that eligible patients are able to access Rxulti®. The medicine is expected to be made available in the first EU markets during first half of 2019.

Brexpiprazole is a once-daily, second-generation (atypical) oral antipsychotic; it provides a combination of partial agonist activity at serotonin 5-HT<sub>1A</sub> and dopamine D<sub>2</sub> receptors, and antagonist activity at serotonin 5-HT<sub>2A</sub> receptors. Brexpiprazole exhibits high affinity for these receptors as well as for noradrenaline alpha<sub>1B/2C</sub> receptors. Brexpiprazole was discovered by Otsuka and is being co-developed by Otsuka and Lundbeck.